Online weight loss treatment can include a clinician review, lifestyle guidance, and prescription medication when medically appropriate. Common options include GLP-1 medications such as semaglutide and tirzepatide, as well as non-GLP-1 drugs. A licensed provider should review BMI, health history, medications, risks, and follow-up needs before prescribing.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →What are online weight loss treatments?
Online weight loss treatment is medical care delivered through telehealth. It may include a health history, BMI review, lifestyle coaching, lab review when needed, prescription medication if appropriate, and follow-up messaging. It should feel convenient, but it should still be real medical care.
How telehealth weight loss care differs from an in-person visit
In a clinic, you may have vital signs taken in person. Online, you usually complete a structured intake, share your height, weight, medications, medical history, and goals, and a licensed clinician reviews whether treatment is appropriate. NIH guidance notes that weight management medications are meant to be used with eating and activity changes, not as a stand-alone fix 1.
What online clinics can and cannot do
Online clinics can review eligibility, prescribe certain medications, monitor side effects, and coordinate home delivery through a pharmacy. They cannot guarantee a prescription, replace emergency care, or safely prescribe when key information is missing. A reputable clinic should make this clear before you pay.
Why prescription medication still requires clinician review
Weight loss medicines can affect digestion, heart rate, blood pressure, glucose, mood, pregnancy planning, and drug absorption. For example, the FDA labels for semaglutide and tirzepatide include warnings about thyroid C-cell tumors in rodents, pancreatitis, gallbladder disease, hypoglycemia when used with insulin or insulin secretagogues, kidney injury related to dehydration, and severe gastrointestinal reactions 2 3.
Who may qualify for prescription weight loss treatment online?
BMI thresholds are often the starting point, but they are not the whole decision. A provider also looks at weight-related conditions, medication interactions, pregnancy status, eating disorder history, gallbladder or pancreas history, and whether online care is safe for you.
Common BMI thresholds used for weight management medications
The National Institute of Diabetes and Digestive and Kidney Diseases says prescription weight management medicines may be considered for adults with BMI of 30 or higher, or BMI of 27 or higher with a weight-related health problem 1. FDA labels for Wegovy (semaglutide, a GLP-1 receptor agonist) and Zepbound (tirzepatide, a GIP/GLP-1 receptor agonist) use similar BMI-based chronic weight management criteria 2 3.
Weight-related conditions a provider may consider
Common weight-related conditions include hypertension, high cholesterol, type 2 diabetes, prediabetes, obstructive sleep apnea, polycystic ovary syndrome, and metabolic dysfunction-associated steatohepatitis, often shortened to MASH 1. The provider’s job is to decide whether the expected benefit is reasonable compared with risks for that person.
Health history that may affect eligibility
A clinician may avoid or delay treatment because of pregnancy, plans for pregnancy, breastfeeding, certain endocrine cancers, pancreatitis history, severe gastrointestinal disease, kidney problems, uncontrolled mental health symptoms, or medication interactions. The labels for semaglutide and tirzepatide also state that they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 2 3.
Why a prescription is never guaranteed
A prescription is a medical decision, not a checkout step. If the risk profile does not fit, a provider may recommend lifestyle care, lab work, in-person evaluation, or a different treatment path.
Which weight loss medications can be prescribed online?
Weight loss medications online can include injectable GLP-1 or GIP/GLP-1 medicines, oral prescription pills, and in some cases medications used off-label. The right option depends on the clinical picture, not just preference.
GLP-1 and GIP/GLP-1 medications
Semaglutide appears in several forms and brands: Wegovy for chronic weight management, Ozempic for type 2 diabetes, and Rybelsus as an oral semaglutide tablet for type 2 diabetes. Tirzepatide appears as Zepbound for chronic weight management and Mounjaro for type 2 diabetes. Ozempic, Rybelsus, and Mounjaro are not FDA-approved for weight loss, though clinicians may sometimes prescribe approved drugs off-label when medically appropriate 2 3 6 7.
Non-GLP-1 prescription pills
Other prescription options include orlistat, sold as Xenical by prescription and Alli over the counter at a lower strength; naltrexone-bupropion, sold as Contrave; phentermine-topiramate, sold as Qsymia; liraglutide, sold as Saxenda; and setmelanotide, sold as Imcivree for rare genetic obesity disorders. Each has its own risks, such as gastrointestinal effects with orlistat, mood and seizure warnings with naltrexone-bupropion, birth-defect risk with phentermine-topiramate, and gallbladder or pancreatitis warnings with liraglutide 8 9 10 11 12.
Injectable vs oral options
Injectable options are common for GLP-1 and GIP/GLP-1 treatment because these peptides are broken down in the gut unless specially formulated. Oral options can be easier for some people, but they may have different absorption rules, side effects, or expected effects depending on the medication and indication 7.
FDA-approved brand medications vs compounded medications
FDA-approved brand medications have FDA-reviewed labeling, manufacturing, and outcomes data for their approved uses. Compounded semaglutide via a 503A pharmacy and compounded tirzepatide via a 503A pharmacy are patient-specific prescriptions prepared by state-licensed compounding pharmacies when clinically appropriate. Compounded formulations are not FDA-approved and do not have FDA-evaluated outcomes data.
How do GLP-1 weight loss treatments work?
GLP-1 medicines work by signaling fullness, slowing gastric emptying, and improving glucose-dependent insulin secretion. Tirzepatide also activates the GIP receptor, which may add metabolic effects, though side effects and contraindications still need close review 2 3.
Appetite, fullness, food noise, and gastric emptying
GLP-1 receptor agonist drugs act on appetite-regulation pathways in the brain and on the stomach. People often describe less hunger or less “food noise,” but the medical mechanisms are satiety signaling and slower gastric emptying. Slower gastric emptying can also cause nausea, vomiting, constipation, reflux, and can affect how some oral medicines are absorbed 2 3.
Semaglutide: Wegovy, Ozempic, and compounded semaglutide
Semaglutide is the active ingredient in Wegovy, Ozempic, and Rybelsus, and it may also be prepared as compounded semaglutide by a 503A pharmacy when prescribed. The FDA-approved Wegovy label starts at 0.25 mg once weekly for 4 weeks and titrates toward maintenance doses of 1.7 mg or 2.4 mg once weekly; this is label information, not dosing advice for any reader 2.
In the STEP 1 trial, adults without diabetes received semaglutide 2.4 mg once weekly plus lifestyle intervention for 68 weeks; the study reported larger average weight loss than placebo, and individual results varied 4. The same trial reported gastrointestinal side effects were more common with semaglutide than placebo, and treatment was stopped more often because of gastrointestinal events 4. Results from STEP 1 apply to semaglutide as studied in that trial, not to compounded formulations.
Tirzepatide: Zepbound, Mounjaro, and compounded tirzepatide
Tirzepatide is the active ingredient in Zepbound and Mounjaro, and it may also be prepared as compounded tirzepatide by a 503A pharmacy when prescribed. The FDA-approved Zepbound label starts at 2.5 mg once weekly for 4 weeks before dose increases; this is label information, not an instruction to use it 3.
In the SURMOUNT-1 trial, adults with obesity or overweight and at least one weight-related complication, but without diabetes, received tirzepatide 5 mg, 10 mg, or 15 mg once weekly plus lifestyle intervention for 72 weeks; average weight loss was greater than placebo, and individual results varied 5. Nausea, diarrhea, constipation, and vomiting were common and happened most often during dose escalation 5. Results from SURMOUNT-1 apply to tirzepatide as studied in that trial, not to compounded formulations.
Why lifestyle habits still matter
FDA labels and clinical trials pair these medications with a reduced-calorie diet and increased physical activity 2 3 4 5. That is not because willpower is the main issue. It is because medication works best as part of a plan that protects nutrition, muscle, sleep, and long-term habits.
3-min quiz
Considering GLP-1 treatment online?
Chia evaluates eligible adults online for compounded semaglutide injection and compounded tirzepatide tablets or injection. A licensed US provider reviews your health history and prescribes only when clinically appropriate; a prescription is never guaranteed. Compounded drugs are not FDA-approved.
How do online weight loss treatment options compare?
Online options differ by medication class, form, approval status, cost path, and monitoring model. A useful comparison looks at benefits and cautions together.
| Option | Examples | Form | Typical use | Key cautions |
|---|---|---|---|---|
| GLP-1 receptor agonist | Wegovy; Saxenda; compounded semaglutide via 503A pharmacy | Usually injection | Chronic weight management when criteria are met | Nausea, vomiting, constipation, gallbladder disease, pancreatitis warnings, contraindications for certain thyroid cancer syndromes 2 11 |
| GIP/GLP-1 receptor agonist | Zepbound; compounded tirzepatide via 503A pharmacy | Usually injection; compounded oral forms may be offered by some clinics | Chronic weight management when criteria are met | GI side effects, gallbladder and pancreatitis warnings, hypoglycemia risk with insulin or sulfonylureas 3 |
| Lipase inhibitor | Orlistat, Xenical, Alli | Oral | Reduces dietary fat absorption | Oily stools, urgency, fat-soluble vitamin issues, rare severe liver injury warning 8 |
| Appetite and reward-pathway pills | Contrave; Qsymia | Oral | May reduce appetite or cravings in selected patients | Blood pressure, heart rate, mood, seizure, pregnancy, and birth-defect warnings vary by drug 9 10 |
| Rare-disease medication | Setmelanotide, Imcivree | Injection | Certain rare genetic obesity conditions | Not for common obesity; requires genetic or clinical criteria 12 |
GLP-1 injections vs oral options
Injections can be a good fit for people who prefer weekly treatment and can use needles safely. Oral options may fit people who do not want injections, but daily schedules, absorption rules, drug interactions, and side effects can be more complex depending on the medicine.
Brand-name medications vs compounded GLP-1s
Brand-name drugs are FDA-approved for the indications on their labels. Compounded GLP-1 prescriptions are prepared for an individual patient by a licensed compounding pharmacy and are not FDA-approved. The safety axis we care about is licensed care: a real clinician evaluation and a state-licensed 503A pharmacy, not no-prescription “research chemical” sources.
Insurance-based care vs cash-pay telehealth
Insurance-based care may lower medication cost if the plan covers the drug, but prior authorization can take time and coverage varies. Cash-pay telehealth can be more predictable, but you should understand visit fees, medication cost, lab cost, shipping, refill rules, and cancellation terms before starting.
What does online weight loss treatment cost?
Online weight loss cost can include visit fees, membership fees, medication, labs, supplies, and shipping. The monthly number can look different depending on whether the program bills insurance, uses manufacturer savings, or offers cash-pay compounded medication.
Visit fees, membership fees, medication costs, and labs
Before paying, look for the full cost: intake visit, follow-up visits, monthly membership, medication, needles or supplies, shipping, labs, and cancellation rules. Some programs separate the visit fee from medication cost. Others bundle services.
How insurance, manufacturer savings cards, and cash-pay pricing differ
Insurance may help with FDA-approved brand medications, but coverage can depend on diagnosis, BMI, prior medication trials, and plan rules. Manufacturer savings cards can change out-of-pocket cost for eligible people, but the terms can change. Cash-pay programs may offer clearer monthly pricing but usually do not count as insurance coverage.
Why compounded medication pricing can differ from brand-name pricing
Compounded medication pricing can differ because it is not the same supply chain as a brand-name pen. The pharmacy, formulation, concentration, service model, and included follow-up can all affect price. A lower price should not replace basic safety checks: licensed clinician, state-licensed 503A pharmacy, clear labeling, and follow-up access.
Questions to ask before paying for an online program
- Will a licensed clinician review my full medical history before any prescription?
- Is a prescription clearly not guaranteed?
- Which pharmacy dispenses the medication, and is it state-licensed?
- What is included in the monthly price?
- How do I report side effects or ask for dose changes?
- What happens if I need labs, urgent care, or in-person evaluation?
Weight loss treatment at Chia: compounded semaglutide and tirzepatide online
At Chia, we evaluate patients online for compounded GLP-1 weight loss treatment when clinically appropriate. Our process is 100% online: you complete a short health questionnaire, a licensed US provider reviews it, and medication is prescribed only when the medical picture fits.
Chia offers semaglutide injection, with plans currently starting at $249/month. We also offer tirzepatide tablets and tirzepatide injection, with tablet plans currently starting at $249/month and injection plans currently starting at $299/month. Microdosing plans are available for compounded semaglutide and tirzepatide when provider-guided; compounded medications and microdosing uses are not FDA-approved.
| Chia option | Forms offered | Current starting price | How it may fit |
|---|---|---|---|
| Semaglutide | Injection | From $249/month | For patients who prefer an injectable GLP-1 path with provider-guided dosing and follow-up |
| Tirzepatide | Tablets and injection | Tablets from $249/month; injection from $299/month | For patients considering a GIP/GLP-1 path, including oral or injectable form options when appropriate |
| Weight + Energy | Compounded NAD+ injection, which is not FDA-approved, plus choice of GLP-1 | From $309/month | For eligible patients whose provider-guided plan includes a GLP-1 and NAD+ injection; see Weight + Energy |
| Weight + Muscle | Compounded sermorelin injection, which is not FDA-approved, plus choice of GLP-1 | From $329/month | For eligible patients whose provider-guided plan includes a GLP-1 and sermorelin injection; see Weight + Muscle |
When prescribed, Chia medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. Patients can message their care team through the patient portal between visits for side effects, progress updates, and provider-guided changes.
What safety issues should you understand before starting?
Safety monitoring is part of weight loss treatment, not an add-on. The same medicine that helps appetite can also cause side effects or become unsafe in the wrong clinical setting.
Common side effects of GLP-1 and GIP/GLP-1 medications
Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, reflux, burping, and reduced appetite. In the STEP 1 and SURMOUNT-1 trials, gastrointestinal side effects were among the most common events, especially during dose increases 4 5.
Serious warnings and when a provider may avoid treatment
A provider may avoid semaglutide or tirzepatide in people with certain thyroid cancer syndromes, serious hypersensitivity, pregnancy, or other risk factors. FDA labels also warn about pancreatitis, gallbladder disease, acute kidney injury linked to dehydration, severe stomach problems, and low blood sugar when used with insulin or insulin-releasing drugs 2 3.
Medication interactions and health conditions to disclose
Tell your provider about diabetes medicines, blood pressure medicines, psychiatric medicines, seizure history, kidney disease, gallbladder disease, pancreatitis, eating disorder history, pregnancy plans, and prior weight loss surgery. Delayed gastric emptying can change absorption of some oral medicines, which is why a medication list matters 2 3.
Why rapid weight loss needs monitoring
Fast weight loss can raise the risk of gallstones and can worsen dehydration, dizziness, constipation, or muscle loss if nutrition is poor; semaglutide and tirzepatide labels also include warnings about gallbladder disease, acute kidney injury related to dehydration, and severe gastrointestinal reactions 2 3. Monitoring helps the care team adjust treatment, protect protein intake and strength training, and decide when symptoms need urgent care.
Follow-up care, dose adjustments, and patient messaging
Follow-up matters because side effects, appetite, weight change, blood pressure, glucose, and tolerability can change over time. Dose changes should be clinician-guided. Online care should make it easy to report vomiting, severe abdominal pain, signs of dehydration, low blood sugar, allergic symptoms, or mood changes.
How can you choose a reputable online weight loss provider?
A reputable provider combines access with guardrails. Look for licensed clinician review, clear pharmacy sourcing, realistic claims, transparent pricing, and ongoing support.
- Licensed clinician review before prescribing, not automatic approval.
- Clear eligibility criteria based on BMI, weight-related conditions, health history, and medication risks.
- Transparent medication sourcing, including whether a state-licensed 503A compounding pharmacy is used.
- Plain pricing that explains what is and is not included.
- A safe way to report side effects and ask questions between visits.
- No guaranteed prescriptions and no guaranteed weight loss claims.
- Clear education on lifestyle support, nutrition, physical activity, and follow-up.
If you are comparing programs, focus less on flashy claims and more on whether the process protects you. Online care should be easier to access, but it should not skip the medical steps.
Yes, some licensed clinicians can prescribe weight loss medication through telehealth after reviewing your BMI, health history, medications, contraindications, and follow-up needs. A prescription is never guaranteed.
There is no single best option for everyone. The right treatment depends on BMI, weight-related conditions, medical history, medication risks, cost, form preference, and how much follow-up support you need.
Yes, semaglutide may be prescribed online when a licensed clinician decides it is appropriate. Chia offers compounded semaglutide injection for eligible patients after online provider review. Compounded drugs are not FDA-approved and do not have FDA-evaluated outcomes data.
Yes, tirzepatide may be prescribed online when medically appropriate. Chia offers compounded tirzepatide tablets and injection for eligible patients after licensed provider review.
No. Compounded medications are not FDA-approved and are not the same as FDA-approved brand-name medications. They should come through a licensed clinician and a state-licensed 503A compounding pharmacy, not a no-prescription source.
Some prescribe injections, some prescribe pills, and some offer both. The right form depends on the medication, your health history, side effects, cost, and clinician judgment.
Some people regain weight after stopping medication, especially if appetite returns and lifestyle support is not maintained; in a STEP 1 semaglutide extension, participants regained some weight after treatment withdrawal 13. Your provider can help plan long-term care, whether that means continuing, adjusting, or stopping treatment.
Yes. AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. A licensed provider still reviews the request, and a prescription is not guaranteed.
3-min quiz
Start your online weight loss visit
If you want a clinician-reviewed path, Chia’s online visit starts with a health questionnaire and licensed provider review. Eligible patients may be prescribed compounded semaglutide injection or tirzepatide tablets or injection through state-licensed 503A pharmacy partners with home delivery. A prescription requires a medical evaluation and is not guaranteed.
References
- 1.National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight & Obesity. 2023.
- 2.Novo Nordisk. Wegovy (semaglutide) injection prescribing information. U.S. Food and Drug Administration. 2024.
- 3.Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. U.S. Food and Drug Administration. 2024.
- 4.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- 5.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- 6.Novo Nordisk. Ozempic (semaglutide) injection prescribing information. U.S. Food and Drug Administration. 2025.
- 7.Novo Nordisk. Rybelsus (semaglutide) tablets prescribing information. U.S. Food and Drug Administration. 2024.
- 8.Genentech USA. Xenical (orlistat) capsules prescribing information. U.S. Food and Drug Administration. 2022.
- 9.Currax Pharmaceuticals. Contrave (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets prescribing information. U.S. Food and Drug Administration. 2021.
- 10.Vivus LLC. Qsymia (phentermine and topiramate extended-release) capsules prescribing information. U.S. Food and Drug Administration. 2022.
- 11.Novo Nordisk. Saxenda (liraglutide) injection prescribing information. U.S. Food and Drug Administration. 2023.
- 12.Rhythm Pharmaceuticals. Imcivree (setmelanotide) injection prescribing information. U.S. Food and Drug Administration. 2022.
- 13.Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
